US President Donald Trump on Friday announced a deal with AstraZeneca PLC that he said would lead to significantly lower domestic drug prices in exchange for granting the pharmaceutical giant tariff relief.
The agreement, which follows a similar accord announced last month with US giant Pfizer Inc, requires AstraZeneca to charge “most-favored nation” pricing — matching the lowest price offered in other wealthy nations — to Medicaid, the US health insurance program for low-income Americans.
Officials also said the British drugmaker had agreed to participate in a Web site called TrumpRx that would allow direct purchasing at reduced prices.
Photo: Bloomberg
Centers for Medicare and Medicaid Services Administrator Mehmet Oz said the drugmaker would also provide “massively” discounted drugs for lung disease.
In exchange, Trump administration officials agreed to a three-year delay on new tariffs on AstraZeneca, which had previously announced plans to invest US$50 billion in the US in response to looming tariff threats.
“Most of our products are locally manufactured, but we need to transfer the remaining part to this country,” said AstraZeneca chief executive officer Pascal Soriot, who appeared with Trump, Oz and other officials at a White House event early Friday night.
The agreement comes on the heels of a Sept. 30 drug price accord with Pfizer that also included three-year tariff relief. Sky-high drug prices are a perennial source of widespread ire in the US, and have sparked numerous legislative and administrative actions the impact of which can be difficult to determine.
Shares of Pfizer and other drugmakers surged after the Sept. 30 announcement, suggesting they are not viewed as a major drag on profits.
“From a company perspective, you have more visibility going forward,” CFRA Research analyst Sel Hardy said. “They know they’ll not be facing tariffs for three years.”
Hardy said it was too early to discern the breadth of the Trump administration’s impact on drug prices in a broad sense.
Part of that would be determined by pricing negotiations next month on 15 leading drugs under legislation signed by former US president Joe Biden in 2022.
Taiwan’s foreign exchange reserves hit a record high at the end of last month, surpassing the US$600 billion mark for the first time, the central bank said yesterday. Last month, the country’s foreign exchange reserves rose US$5.51 billion from a month earlier to reach US$602.94 billion due to an increase in returns from the central bank’s portfolio management, the movement of other foreign currencies in the portfolio against the US dollar and the bank’s efforts to smooth the volatility of the New Taiwan dollar. Department of Foreign Exchange Director-General Eugene Tsai (蔡炯民)said a rate cut cycle launched by the US Federal Reserve
Handset camera lens maker Largan Precision Co (大立光) on Sunday reported a 6.71 percent year-on-year decline in revenue for the third quarter, despite revenue last month hitting the highest level in 11 months. Third-quarter revenue was NT$17.68 billion (US$581.2 million), compared with NT$18.95 billion a year earlier, the company said in a statement. The figure was in line with Yuanta Securities Investment Consulting Co’s (元大投顧) forecast of NT$17.9 billion, but missed the market consensus estimate of NT$18.97 billion. The third-quarter revenue was a 51.44 percent increase from NT$11.67 billion in the second quarter, as the quarter is usually the peak
The US government on Wednesday sanctioned more than two dozen companies in China, Turkey and the United Arab Emirates, including offshoots of a US chip firm, accusing the businesses of providing illicit support to Iran’s military or proxies. The US Department of Commerce included two subsidiaries of US-based chip distributor Arrow Electronics Inc (艾睿電子) on its so-called entity list published on the federal register for facilitating purchases by Iran’s proxies of US tech. Arrow spokesman John Hourigan said that the subsidiaries have been operating in full compliance with US export control regulations and his company is discussing with the US Bureau of
Pegatron Corp (和碩), a key assembler of Apple Inc’s iPhones, on Thursday reported a 12.3 percent year-on-year decline in revenue for last quarter to NT$257.86 billion (US$8.44 billion), but it expects revenue to improve in the second half on traditional holiday demand. The fourth quarter is usually the peak season for its communications products, a company official said on condition of anonymity. As Apple released its new iPhone 17 series early last month, sales in the communications segment rose sequentially last month, the official said. Shipments to Apple have been stable and in line with earlier expectations, they said. Pegatron shipped 2.4 million notebook
RSS